Abstract

BackgroundUp to 40% of patients with inflammatory arthritis on TNF-α inhibitor (TNFi) treatment fail to respond either due to primary inefficacy or loss of response. One explanation is immunogenicity leading...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
THU0208 Efficacy of Switching Tumor Necrosis Factor α Inhibitor to a Second Tumor Necrosis Factor α Inhibitor and the Influence of Drug Levels and Anti-Drug Antibodies in Patients with Ankylosing Spondylitis and Psoriatic Arthritis
M.T Nurmohamed ... I.E Van Der Horst-Bruinsma
Annals of the Rheumatic Diseases | VOL. 74
M.T Nurmohamed, et. al.M.T Nurmohamed ... I.E Van Der Horst-Bruinsma
01 Jun 2015
POS0345 ADALIMUMAB SERUM DRUG LEVELS AND ANTI-DRUG ANTIBODIES: ASSOCIATION TO DISEASE ACTIVITY AND DRUG SURVIVAL IN INFLAMMATORY ARTHRITIS PATIENTS
J E Gehin ... E Kristianslund
-
J E Gehin, et. al.J E Gehin ... E Kristianslund
30 May 2023
Antidrug Antibodies to Tumor Necrosis Factor α Inhibitors in Patients With Noninfectious Uveitis
Wijak Kongwattananon ... Sunil Bellur
JAMA Ophthalmology | VOL. 141
Wijak Kongwattananon, et. al.Wijak Kongwattananon ... Sunil Bellur
22 Dec 2022
AB0573 The immunogenicity of biological therapies correlates with clinical efficacy in psoriatic arthritis (psa) in long-term treatment with infliximab and adalimumab.
M T López-Casla ... A Balsa
Annals of the Rheumatic Diseases | VOL. 72
M T López-Casla, et. al.M T López-Casla ... A Balsa
01 Jun 2013
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers